Sign in
Taking people in United StatesNo phase

Following people with sickle cell disease as they move into adulthood

Observes people with sickle cell disease over time, including through adulthood, to study organ changes.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Baton Rouge, Charlotte, Memphis, and Peoria, United StatesSee the 6 sites
Trial code
Registry title
Sickle Cell Clinical Research and Intervention Program
Status
Recruiting
People taking part
10,000 people, planned
Started
15 Apr 2014
Expected to end
Dec 2044
Type of study
Observational
Record updated
4 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with sickle cell disease of any genotype. It follows them at regular clinic visits. Some can also join a hydroxyurea blood-level sub-study.

Sex
Everyone can join, any sex.
Disease stage
Sickle cell disease of any genotype.
Earlier treatment
Only for the hydroxyurea (HU) sub-study: currently taking HU, at the maximum tolerated dose for at least 90 days before joining.

Main reasons for not taking part

  • Any medical or social reason that the principal investigators think makes taking part ill-advised.
  • Sub-study: cannot complete the blood draws needed for the PK sampling.
  • Sub-study: the participant or legal guardian cannot or will not give written informed consent.

The registry criteria, word for word

Show all 5 criteriaShow less

Other criteria

  • SCCRIP Inclusion Criteria:
  • A diagnosis of sickle cell disease of any genotype
  • PK Sub-study Inclusion Criteria:; Participants at St. Jude Children's Research Hospital who are consented to the parent protocol (SCCRIP, Amendment 6.1 or above); Participants currently completing a hydroxyurea (HU) regimen, who have achieved maximum tolerated dose and have maintained that dose for a minimum of 90 days prior to enrollment; SCCRIP Exclusion Criteria:
  • Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised
  • PK Sub-study Exclusion Criteria:; Participants unable to complete the blood draws required for PK sampling; Inability or unwillingness of research participant or legal guardian/representative to give written informed consent; Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised

Where in United States

  • Our Lady of the Lake Regional Medical CenterBaton Rouge, United StatesContact: Deepa Manwani, MDNo longer taking part
  • Novant Health - Hemby Children's HospitalCharlotte, United StatesContact: Felipe Bautista Otanez, MDTaking people
  • Methodist Adult Comprehensive Sickle Cell CenterMemphis, United StatesContact: Marquita D. Nelson, MDTaking people
  • Regional One Health, Diggs-Kraus Sickle Cell CenterMemphis, United StatesContact: Ugochi Ogu, MDTaking people
  • St. Jude Children's Research HospitalMemphis, United StatesContact: Deepa Manwani, MDTaking people
  • Children's Hospital of Illinois at OSF-Saint Francis Medical CenterPeoria, United StatesContact: Kay Saving, MDTaking people

About the trial

What the trial wants to find out

Despite the important work of previous sickle cell disease (SCD) cohort studies, there remain many understudied areas that require investigation. An important knowledge deficit is the slow but progressive process of chronic end-organ dysfunction. The majority of organ dysfunction becomes apparent in the young adult years, but comprehensive assessment of adults and understanding of predictors of adulthood organ dysfunction are insufficient. Similarly, the role of disease-modifying therapies, such as hydroxyurea, in preventing organ dysfunction later in life is not clear. Extended follow-up of patients through the transition into adulthood is imperative to understand the long-term implications of pediatric sickle cell care.

Read full original descriptionShow less

This observational study will collect data in a systematic fashion at participants' regular clinic visits (in-person or remote) to answer the objectives described below.

In addition to primary study objectives, SCCRIP participants will be eligible to participate in a sub-study, which will investigate genetically determined responses to Hydroxyurea (HU) via a pharmacokinetic study (PK). This one time study will involve blood collection at timed intervals proceeding a dose of HU. Defining the basis for this inter-individual variability will allow the identification of poor HU responders prior to initiation of therapy and the seeking of alternative treatments which seek to optimize disease treatment by accounting for individual variability in genes, environment, and lifestyle.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sickle Cell Clinical Research and Intervention Program
Plain-language title
Following people with sickle cell disease as they move into adulthoodGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
4 June 2026